---
title: "Zhejiang Medicine released its 2024 annual performance, with a net profit attributable to the parent company of 1.161 billion yuan, a year-on-year increase of 170.11%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237129830.md"
description: "Zhejiang Medicine released its 2024 annual performance report, with revenue of 9.375 billion yuan, a year-on-year increase of 20.29%; net profit attributable to shareholders of the parent company was 1.161 billion yuan, a year-on-year increase of 170.11%; net profit excluding non-recurring gains and losses was 1.16 billion yuan, a year-on-year increase of 656.77%; basic earnings per share were 1.21 yuan. The company plans to distribute a cash dividend of 0.37 yuan per share (including tax) to all shareholders"
datetime: "2025-04-23T09:13:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237129830.md)
  - [en](https://longbridge.com/en/news/237129830.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237129830.md)
---

# Zhejiang Medicine released its 2024 annual performance, with a net profit attributable to the parent company of 1.161 billion yuan, a year-on-year increase of 170.11%

According to the Zhitong Finance APP, Zhejiang Medicine (600216.SH) disclosed its 2024 annual report. During the reporting period, the company achieved revenue of 9.375 billion yuan, a year-on-year increase of 20.29%; net profit attributable to shareholders was 1.161 billion yuan, a year-on-year increase of 170.11%; net profit excluding non-recurring gains and losses was 1.16 billion yuan, a year-on-year increase of 656.77%; basic earnings per share were 1.21 yuan. The company plans to distribute a cash dividend of 0.37 yuan per share (including tax) to all shareholders

### Related Stocks

- [600216.CN](https://longbridge.com/en/quote/600216.CN.md)

## Related News & Research

- [3 Gold-Rated Index Funds We Love Right Now](https://longbridge.com/en/news/286821241.md)
- [BREAKINGVIEWS-China's outbound M&A spree has staying power](https://longbridge.com/en/news/286850954.md)
- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [PRECIOUS-Gold falls to 1-1/2-month low on higher US yields, firm dollar](https://longbridge.com/en/news/287016248.md)